2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
John M. Burke, MD, discusses risk stratifications strategies in follicular lymphoma.
John M. Burke, MD, associate chair of the Hematology Research Program for US Oncology and medical oncologist and hematologist at Rocky Mountain Cancer Centers, discusses risk stratifications strategies in follicular lymphoma.
Risk stratification can be done in several ways, says Burke. For example, patients can be stratified as having low versus high tumor burden and according to disease stage.
Further, the Follicular Lymphoma International Prognostic Index (FLIPI), the FLIPI2 score, and the M7-FLIPI score, which incorporates results from gene sequencing to understand what mutations cancer cells harbor, are utilized, Burke explains.
Although these strategies are commonly used in the space, each are associated with some flaws with regard to risk stratification, Burke concludes.